Keyphrases
Neuromyelitis Optica
100%
Aquaporin-4 (AQP4)
36%
Neuromyelitis Optica Spectrum Disorder (NMOSD)
27%
Diagnostic Work-up
18%
Second-line Treatment
9%
Spinal Cord
9%
Expert Discussion
9%
Brain Magnetic Resonance Imaging
9%
Clinical Presentation
9%
Multiple Sclerosis
9%
Autoimmune Disease
9%
Optical Coherence Tomography
9%
Disease Entity
9%
Clinical Variants
9%
Imaging Techniques
9%
Imaging Modalities
9%
Group Meetings
9%
Safety Profile
9%
New Therapies
9%
Antibody Test
9%
Mitoxantrone
9%
Current Guidelines
9%
Methotrexate
9%
Immunosuppressive Drugs
9%
IL-6 Receptor
9%
Rituximab
9%
Brain Lesions
9%
Mycophenolate Mofetil
9%
Long-term Efficacy
9%
Literature Discussion
9%
Acceptable Safety
9%
Neuromyelitis optica-IgG
9%
Devic's Syndrome
9%
Retinal Damage
9%
Anticomplement
9%
Anti-IL-6
9%
On-state Current
9%
Neuroscience
Neuromyelitis Optica
100%
Aquaporin 4 Antibody
26%
Magnetic Resonance Imaging
6%
Multiple Sclerosis
6%
Autoimmune Disease
6%
Imaging Technique
6%
Brain Lesion
6%
Spectrum Disorder
6%
Methotrexate
6%
Azathioprine
6%
Rituximab
6%
Mitoxantrone
6%
Immunosuppressive Drug
6%
Receptor
6%
Mycophenolate Mofetil
6%
Pharmacology, Toxicology and Pharmaceutical Science
Myelooptic Neuropathy
100%
Aquaporin 4 Antibody
26%
Mitoxantrone
6%
Receptor
6%
Immunosuppressive Agent
6%
Methotrexate
6%
Biological Product
6%
Mycophenolate Mofetil
6%
Rituximab
6%
Azathioprine
6%
Retina Injury
6%
Autoimmune Disease
6%
Multiple Sclerosis
6%
Diseases
6%